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The diameter of an abdominal aortic aneurysm (AAA) is the single most important factor in deciding whether to repair
an aneurysm or to monitor it conservatively. Open surgical repair does not appear to be beneficial until the diameter of
the aneurysm is >5.5 cm. Prospective clinical trials, however, confirmed a lower risk of operative mortality after
endovascular aneurysm repair (EVAR) than after open surgical repair. Further, retrospective analyses of EVAR databases
suggested that EVAR outcome is directly related to aneurysm size and is better for smaller aneurysms than for larger
aneurysms. Noting similar results with open surgical management vs surveillance in patients with smaller AAA, lower
morbidity rates with EVAR vs open repair, and the favorable results with EVAR in smaller aneurysms, a clinical trial
testing the hypothesis that EVAR is beneficial in patients with small AAA appeared warranted. To answer this question,
the 70-site Positive Impact of endoVascular Options for Treating Aneurysm earLy (PIVOTAL) was begun. PIVOTAL
has an enrollment goal of up to 1025 patients with a 4- to 5-cm AAA, randomly assigning patients to EVAR or
surveillance. The primary end points of PIVOTAL are aneurysm rupture and AAA-related death at up to 36 months after
randomization. When complete, the results of PIVOTAL should provide objective evidence to guide the use of EVAR for
small AAAs. (J Vasc Surg 2009;49:266-9.)Elective abdominal aortic aneurysm (AAA) repair is a
prophylactic procedure designed to prevent aneurysm rup-
ture. Like any therapeutic endeavor, its success must be
gauged by the safety of the procedure itself and by its
long-term effectiveness in preventing rupture. It is not
surprising that the earliest attempts at AAA repair were
neither safe nor effective. For instance, wrapping and wiring
of aneurysms, procedures developed in the first half of the
20th century, were associated with high procedural morbidity
without a sufficient reduction in the risk of rupture.1
Even today, the morbidity and mortality of aneurysm
repair can be considerable, especially in compromised pa-
tients. Although excellent outcome has been achieved in
high-volume tertiary referral centers, mortality rates as high
as 7% and perioperative morbidity rates of up to 50% or
more persist in some communities.2 Even higher rates of
complications are observed in patients with significant car-
diac, pulmonary, or renal dysfunction.3,4 For this reason,
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266aneurysm repair has been reserved for select patients,
weighing the risk of rupture against the morbidity and
mortality of the procedure.
The diameter of an aneurysm is perhaps the single most
important variable predicting rupture and, as such, is the
primary consideration when recommending repair or ob-
servation to patients with aneurysms.5-7 Several random-
ized clinical trials have identified an AAA size of 5.5 cm as a
reasonable threshold for recommending open surgical re-
pair. Nevertheless, if a procedure with zero morbidity and
uniform durability were available, all aneurysms would be
treated, irrespective of size.
By contrast, the two currently available techniques for
aneurysm repair—open and endovascular (EVAR)—are
associated with significant operative risk and far from con-
sistent durability. Given that the decision to repair an
aneurysm in a specific patient is determined by weighing
the risk of rupture against the risks of the procedure, less
morbid techniques might be offered to patients with
smaller aneurysms. Intuitively, EVAR should be associated
with lower perioperative morbidity than open surgery. As
long as the long-term durability of EVAR in preventing
postrepair aneurysm rupture is low, a reduced perioperative
complication rate might tip the balance in favor of repair
over surveillance for small AAAs.
Studies of EVAR vs open repair have been conflicting.
Retrospective analyses of large patient cohorts have almost
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Volume 49, Number 1 Ouriel 267uniformly identified lower mortality with EVAR,8 but the
two well-powered randomized clinical trials have not dem-
onstrated such a difference.9,10 The randomized studies,
however, included patients with larger as well as smaller
aneurysms, and some data suggest that EVAR for small
aneurysms is associated with extremely low procedural
morbidity.11,12 With these concepts in mind, randomized
studies were organized to determine whether benefit exists
for EVAR vs observation in patients with smaller AAA.
OPEN REPAIR VS SURVEILLANCE IN SMALL
AORTIC ANEURYSMS
Two prospective clinical trials have compared surveil-
lance with open repair of 4- to 5.5-cm AAAs: the Aneurysm
Detection and Management (ADAM) trial13 and United
Kingdom Small Aneurysm Trial (UKSAT).13-15 The con-
clusions of the trials were similar: no benefit of early open
surgical repair was conferred in patients with a small AAA
(Table I). In UKSAT, this conclusion was reached despite a
statistically significant improvement in long-term survival
with early open repair. This finding, however, was present
at a single time point and was considered to be a result of
lifestyle modification in the surgical group (eg, smoking
cessation), rather than to a direct reduction in the rate of
rupture. Of note, the perioperative mortality rates associ-
ated with open repair were quite high in both trials: 2.1% in
ADAM and 5.4% in UKSAT.
OPEN REPAIR VS EVAR IN LARGER
ANEURYSMS
The high operative mortality rate of open repair in
ADAM and in UKSAT raised the question whether simi-
larly designed trials that substitute EVAR for open repair
might demonstrate a benefit for early repair. Two random-
ized trials compared EVAR with open surgery for the
treatment of AAAs 5.5 cm in diameter. The Comparison of
Endovascular Aneurysm Repair with Open Repair in Pa-
tients with Abdominal Aortic Aneurysm (EVAR-1) trial9,16
and the Dutch Randomised Endovascular Aneurysms
Table I. Results of randomized trials of open repair vs sur
Variable
ADAM13
Early open repair
Patients, No. 569
AAA size, mean  SD, cm 4.7  0.4
Age, mean  SD, y 68  5.9
30-day mortality, % 2.7
3-year, % 88
5-year variables, %b
Survival 78
AAA-related mortality 3
Reintervention 1.7
AAA rupture 0.4
AAA,Abdominal aortic aneurysm;ADAM,AneurysmDetection andManag
aPatients who later required open repair.
bBased on Kaplan-Meier analysis.(DREAM) trial10,17 documented lower in-hospital andoperative mortality rates for EVAR, but the survival benefit
was not sustained over time. In the 1082-patient EVAR-1
study, the 30-day mortality rate was 1.7% for EVAR vs 4.7%
for open repair (P  .001). At 4 years, all-cause mortality
was similar for EVAR (26%) and open repair (29%; P 
.46), but the aneurysm-related mortality rate for EVAR
(4%) was almost half of that for open repair (7%; P 0.04).
Similarly, in the 351-patient DREAM trial, the 30-day
mortality rate was 1.2% after EVAR vs 4.6% after open
repair, but overall survival rates were not different at 2
Table II. Study design of the PIVOTAL trial
Sites, No. 70
Patients, No Up to 1025
Endograft device AneuRx/Talent
Aneurysm diameter, cm 4.0 to 5.0
Follow-up, months 1, 6, 12, 18, 24, 36
Triggers in surveillance arm
for AAA repair
5.5 cm, 0.5 cm/6 mo, 1.0
cm/y, or symptomatic
Primary end points AAA rupture up to 3 years; AAA-
related death up to 3 years
Selected secondary end
points
All-cause and AAA-related
mortality in smokers vs
nonsmokers; conversion to
open surgical repair
Inclusion criteria Eligible for EVAR per instructions
for use of endograft system, age
40 to 90 years, candidates at
low to moderate risk per
SVS/AAVS comorbidity
scoring system
Exclusion criteria TAA 5.0 cm; MI without
revascularization 6 months or
with revascularization 30 days
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair;
MI, myocardial infarction; PIVOTAL, Positive Impact of endoVascular
Options for Treating Aneurysm earLy; SVS/AAVS, Society for Vascular
Surgery/American Association for Vascular Surgery; TAA, thoracic aortic
aneurysm.
nce for treatment of small abdominal aortic aneurysms
UKSAT13-15
rveillance Early open repair Surveillance
567 563 527
4.7  0.4 4.61  0.37 4.63  0.40
7.8  6.4 69.2  4.4 69.3  4.4
2.1a 5.8 7.1a
91 84 84
82 72 68
2.6 5.7 6.6
60.0 NA 65
1.9 NA 3.2
t Study;UKSAT,United Kingdom Small AneurysmTrial;NA, not available.veilla
Su
6
emenyears.
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SURVEILLANCE IN PATIENTS WITH
SMALL AAA
The PIVOTAL trial is a prospective 70-site trial of early
EVAR using the AneuRx or Talent devices (Medtronic,
Santa Rosa, Calif) vs surveillance for treatment of AAAs 4-
to 5-cm in diameter. Funded by Medtronic Vascular, the
study and its analysis are being performed independently by
the Cleveland Clinic (Table II).
The plan calls for a 1050-patient sample size, 525 in
each group, calculated on an assumed rate of the primary
end points of (1) aneurysm rupture and (2) the composite
outcome of AAA-related death up to 3 years. Data from the
ADAM and UKSAT trials documented a 3-year event rate
of 5.1% in surveilled patients with small aneurysms, linearly
extrapolated to 1.7% annually. The Cleveland Clinic EVAR
database11 was used to calculate a 3-year composite event
rate of 2.1%, corresponding to an annualized rate of 0.7%.
These event rates corresponded to a hazard ratio of 0.42
(0.71%/1.7%) for surveillance vs EVAR in patients with
small aneurysms. For power calculations, a constant hazard
ratio was assumed over time; actual analyses will account for
nonconstant hazard in either or both groups. Sample size
calculation used a hazard ratio of 0.42, with 80% power at
the 0.05 significance level, and assumed that 18% of pa-
tients would be lost to follow-up over 3 years.
Major inclusion criteria are the ability to meet all the
indications for use for the endograft, age 40 to 90 years,
and a low to moderate risk according to the Society for
Vascular Surgery/American Association for Vascular Sur-
gery comorbidity scoring system.18 Eligible patients must
also have a life expectancy of at least 3 years. Exclusion
criteria are designed to preclude the enrollment of patients
who have aneurysm anatomy not amenable to treatment
with an endograft and any patients with comorbidities that
would complicate repair or result in inordinate operative
risk. Patients are excluded who have any planned surgical or
interventional procedure 30 days after enrollment, a
myocardial infarction without revascularization6months
or with revascularization 30 days before enrollment, a
known iliac aneurysm3.0 cm, or a known thoracic aneu-
rysm 5.0 cm.
In addition to the primary end points of rupture and
AAA-related death, secondary end points include assess-
ment of mortality in smokers vs nonsmokers, conversion to
open surgical repair, successful deployment of the en-
dograft, endograft occlusion, endoleak 1 year, aneurysm
shrinkage or growth, quality of life, and occurrence of
serious adverse events. An economic substudy will also
compare medical resource usage and associated costs in the
EVAR and surveillance groups.
Enrolled patients undergo randomization to early re-
pair or surveillance. Patients in the surveillance arm of
PIVOTAL are assessed at 6, 12, 18, 24, 30, and 36 months
by ultrasound imaging or computed tomography. Surveil-
lance patients will be eligible for EVAR or open repair when
they become symptomatic or the AAA diameter reaches 5.5cm or enlarges by 0.5 cm in 6 months or by 1.0 cm in
a year. All patients are monitored for at least 3 years or until
a primary end point is reached. As of November 2008, just
over 700 patients have been enrolled in the study. The trial
is expected to complete enrollment within the next year.
LOGIC INHERENT IN THE PIVOTAL
STUDY DESIGN
The DREAM, EVAR-1, and a number of retrospective
studies documented lower perioperative mortality rates in
EVAR compared with open repair of larger aneurysms.
ADAM and UKSAT demonstrated similar long-term re-
sults after open operation vs surveillance in patients with
smaller aneurysms. If outcomes after EVAR are better in
patients with smaller vs larger aneurysms as suggested from
retrospective database analyses,11,12,19-21 then survival af-
ter EVARmight actually be improved in patients with small
aneurysms.
Smaller AAAs can be more favorable for EVAR as a
result of suitable aortic anatomy. In one study, AAAs5.5
cm had longer necks, less angulation, less tortuosity, and
longer iliac landing zones than AAAs5.5 cm.20With each
1-cm increase in diameter, anatomic suitability for EVAR
decreased fivefold. Thus, some candidates for EVAR at
AAA diameters of 4 to 5.5 cm might no longer be suitable
when diameters are 5.5 cm and thus might be subject to
the increased risks of open repair performed at a time when
the patients are older and less fit for a major invasive
procedure.
In the future, we hope to be able to individualize the
threshold for intervention in patients with AAA on the basis
of the risk of rupture, operative morbidity and mortality,
life expectancy, and the durability of repair. Aneurysm
diameter is likely to be a critical variable in weighing the
relative importance of all four factors. In addition to
PIVOTAL, the European-based 17-site Comparison of
Surveillance vs Aortic Endografting for Small Aneurysm Re-
pair (CAESAR) trial seeks to enroll 740 patients with AAA
between 4 and 5.5 cm in diameter, randomizing between
surveillance and EVAR with the Zenith device (Cook,
Bloomington, Ind).22 We anticipate substantial guidance
toward that end will be gained when the PIVOTAL and
CAESAR trials are complete, for the first time providing
objective data on which to base clinical decisions in patients
with small infrarenal AAAs.
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